臨床整形外科57巻11号

2022年11月発行

特集 腰椎椎間板ヘルニアのCutting Edge

椎間板ヘルニア後の再生を目指して—椎間板再生医療等製品開発の現状

著者： 酒井大輔¹

所属機関： ¹東海大学医学部外科学系整形外科学

ページ範囲：P.1295 - P.1300

椎間板変性症に伴って発症する椎間板ヘルニアは働き盛りの壮年期に好発し，社会的インパクトも大きい疾患であるが，その治療は保存的治療が無効な場合，組織の切除しかないのが実情である．椎間板ヘルニア手術後に椎間板変性が進行することが示されており，その抜本的対策として椎間板再生医療の実現が望まれる．本稿では椎間板再生の機序，臨床応用までの道筋と臨床試験の現状について紹介する．

参考文献

1) Shiga Y. The essence of clinical practice guidelines for lumbar disc herniation, 2021:1. Epidemiology and natural course. Spine Surgery and Related Research 2022;6(4):319-21.

2) Sakai D. The essence of clinical practice guidelines for lumbar disc herniation, 2021:4. Treatment. Spine Surgery and Related Research 2022;6(4):329-32.

3) Sakai D, Schol J, Watanabe M. Clinical development of regenerative medicine targeted for intervertebral disc disease. Medicina (Kaunas) 2022;58(2):267.

4) Hiraishi S, Schol J, Sakai D, et al. Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine model. JOR Spine 2018;1(2):e1013. doi:10.1002/jsp2.1013.

5) Nukaga T, Sakai D, Schol J, et al. Annulus fibrosus cell sheets limit disc degeneration in a rat annulus fibrosus injury model. JOR Spine 2019;2(2):e1050. doi:10.1002/jsp2.1050.

6) Vickers L, Thorpe AA, Snuggs J, et al. Mesenchymal stem cell therapies for intervertebral disc degeneration:consideration of the degenerate niche. JOR Spine 2019;2(2):e1055. doi:10.1002/jsp2.1055.

7) Sakai D, Schol J. Cell therapy for intervertebral disc repair:clinical perspective. J Orthop Transl 2017;9:8-18.

8) Piccirilli M, Delfinis CP, Santoro A, et al. Mesenchymal stem cells in lumbar spine surgery:a single institution experience about red bone marrow and fat tissue derived MSCs. J Neurosurg Sci 2017;61(2):124-33.

9) Kumar H, Ha DH, Lee EJ, et al. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain:1-year follow-up of a phase I study. Stem Cell Res Ther 2017;8(1):262.

10) Henriksson HB, Papadimitriou N, Hingert D, et al. The traceability of mesenchymal stromal cells after injection into degenerated discs in patients with low back pain. Stem Cells Dev 2019;28(17):1203-11.

11) Wang P, Li Y, Huang L, et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs:A 20-week clinical trial. Cell Transplant 2014;23(10):1293-303.

12) Yoshikawa T, Ueda Y, Miyazaki K, et al. Disc regeneration therapy using marrow mesenchymal cell transplantation:a report of two case studies. Spine (Phila Pa 1976) 2010;35(11):E475-80. doi:10.1097/BRS.0b013e3181cd2cf4.

13) Garcia-Sancho J, Sanchez A, Vega A, et al. Influence of HLA matching on the efficacy of allogeneic mesenchymal stromal cell therapies for osteoarthritis and degenerative disc disease. Transplant Direct 2017;3(9):e205. doi:10.1097/TXD.0000000000000724.

14) Noriega DC, Ardura F, Hernández-Ramajo R, et al. Intervertebral disc repair by allogeneic mesenchymal bone marrow cells:a randomized controlled trial. Transplantation 2017;101(8):1945-51.

15) Orozco L, Soler R, Morera C, et al. Intervertebral disc repair by autologous mesenchymal bone marrow cells:a pilot study. Transplantation 2011;92(7):822-8.

16) Centeno C, Markle J, Dodson E, et al. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells:a pilot study on safety and efficacy. J Transl Med 2017;15(1):197.

17) Elabd C, Centeno CJ, Schultz JR, et al. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain:a long-term safety and feasibility study. J Transl Med 2016;14(1):253. doi:10.1186/s12967-016-1015-5.

18) Amirdelfan K, Bae H, McJunkin T, et al. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease:a prospective randomized, placebo-controlled 36-month study of safety and efficacy. Spine J 2021;21(2):212-30.

19) Pang X, Yang H, Peng B. Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain. Pain Physician 2014;17(4):E525-30.

20) Mochida J, Sakai D, Nakamura Y, et al. Intervertebral disc repair with activated nucleus pulposus cell transplantation:A three-year, prospective clinical study of its safety. Eur Cell Mater 2015;29:202-12.

21) Coric D, Pettine K, Sumich A, et al. Prospective study of disc repair with allogeneic chondrocytes presented at the 2012 Joint Spine Section Meeting. J Neurosurg Spine 2013;18(1):85-95.

22) Meisel HJ, Ganey T, Hutton WC, et al. Clinical experience in cell-based therapeutics:Intervention and outcome. Eur Spine J 2006;15 (Suppl 3):S397-405.

23) Meisel HJ, Siodla V, Ganey T, et al. Clinical experience in cell-based therapeutics:disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc. Biomol Eng 2007;24(1):5-21.

24) Tschugg A, Diepers M, Simone S, et al. A prospective randomized multicenter phase I/II clinical trial to evaluate safety and efficacy of NOVOCART disk plus autologous disk chondrocyte transplantation in the treatment of nucleotomized and degenerative lumbar disks to avoid secondary disease:Safety results of Phase I-a short report. Neurosurg Rev 2017;40(1):155-62.

25) Tschugg A, Michnacs F, Strowitzki M, et al. A prospective multicenter phase I/II clinical trial to evaluate safety and efficacy of NOVOCART Disc plus autologous disc chondrocyte transplantation in the treatment of nucleotomized and degenerative lumbar disc to avoid secondary disease:study protocol for a randomized controlled trial. Trials 2016;17(1):108.

26) Beall DP, Wilson GL, Bishop R, et al. VAST clinical trial:safely supplementing tissue lost to degenerative disc disease. Int J Spine Surg 2020;14(2):239-53.

27) Beall DP, Davis T, DePalma MJ, et al. Viable disc tissue allograft supplementation:one- and two-level treatment of degenerated intervertebral discs in patients with chronic discogenic low back pain:one year results of the VAST randomized controlled trial. Pain Physician 2021;24(6):465-77.

28) Hunter CW, Guyer R, Froimson M, et al. Effect of age on outcomes after allogeneic disc tissue supplementation in patients with chronic discogenic low back pain in the VAST trial. Pain Manag 2022;12(3):301-11.

29) Rustenburg CME, Faraj SSA, Ket JCF, et al. Prognostic factors in the progression of intervertebral disc degeneration:Which patient should be targeted with regenerative therapies? JOR Spine 2019;2(3):e1063. doi:10.1002/jsp2.1063.